Quick Answer: Semaglutide targets one hormone receptor and produced 14.9% weight loss in landmark trials. Tirzepatide targets two receptors and produced up to 20.9%. Retatrutide targets three receptors and showed 24.2% in Phase 2 — and 28.7% in the first Phase 3 results announced in December 2025. Retatrutide is not FDA-approved and remains available only through clinical trials. Telezen MD currently offers both semaglutide and tirzepatide, compounded through 503A FDA-regulated pharmacies.
A new generation of weight-loss medications is reshaping what is medically possible in treating obesity. Three names are at the center of that conversation in 2026: semaglutide, tirzepatide, and the highly anticipated retatrutide.
Each one works differently. Each one has a different approval status. For patients deciding where to start, those differences matter far more than the headlines suggest. This article breaks down all three — how they work at the receptor level, what clinical trials have shown, how side effects compare, and what is actually available right now.
What Makes These Three Drugs Different?
At their core, all three are incretin-based therapies. They mimic hormones your gut naturally releases after eating — hormones that signal the brain to reduce hunger, slow digestion, and regulate blood sugar. What separates them is the number of receptor targets each molecule activates.
- Semaglutide activates one receptor: GLP-1
- Tirzepatide activates two receptors: GLP-1 and GIP
- Retatrutide activates three receptors: GLP-1, GIP, and glucagon
Each added receptor target has tracked with greater weight loss in trials — alongside a more complex side-effect profile. Understanding that tradeoff is central to understanding why these drugs are not interchangeable.
How Each Drug Works
Semaglutide: The Single-Receptor Pioneer
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone released by the gut after eating. It signals the brain to reduce hunger, prompts the pancreas to release insulin, and slows gastric emptying — meaning you stay fuller for longer on less food.
Semaglutide is a synthetic, long-acting version of that hormone, designed to stay active in the body for approximately seven days. It is injected once weekly.
Brand names include Wegovy (approved for chronic weight management) and Ozempic (approved for type 2 diabetes). As of 2026, semaglutide is the only weight-loss medication to carry a cardiovascular risk-reduction indication, based on the SELECT trial, which demonstrated a 20% reduction in major cardiac events in adults with obesity and established cardiovascular disease.
Telezen MD provides access to compounded semaglutide through a 503A FDA-regulated pharmacy: telezenmd.com/semaglutide.
Tirzepatide: The Dual-Agonist Advantage
Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors with a single molecule. GIP is a second gut hormone involved in fat metabolism and insulin sensitivity. Activating both simultaneously produces results that go beyond a single-receptor approach.
Brand names are Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management, and more recently for moderate-to-severe sleep apnea). Tirzepatide received FDA approval for obesity in 2023 and has quickly become one of the most clinically studied medications in the weight-loss space.
In the SURMOUNT-5 trial — the only direct randomized comparison between tirzepatide and semaglutide — tirzepatide at 15mg produced 20.2% mean body weight loss versus 13.7% for semaglutide at 2.4mg over 72 weeks in adults with obesity and no type 2 diabetes.
Telezen MD also offers tirzepatide through a 503A pharmacy: telezenmd.com/tirzepatide-prescription-online. For a detailed side-by-side, see our semaglutide vs. tirzepatide weight-loss comparison.
Retatrutide: The Triple-Agonist Contender (Not Yet Available)
Retatrutide (LY3437943), developed by Eli Lilly, adds a third receptor: the glucagon receptor. Glucagon is a hormone that raises energy expenditure and drives fat metabolism. When activated alongside GLP-1 and GIP, it appears to produce weight loss beyond what either the single- or dual-agonist approach achieves.
This triple mechanism has earned retatrutide the informal shorthand “GLP-3,” though its formal designation is triple hormone receptor agonist.
In Phase 2 trials (NEJM, 2023), retatrutide at 12mg produced 24.2% mean body weight loss at 48 weeks. The first Phase 3 result, from the TRIUMPH-4 trial announced by Eli Lilly in December 2025, reported 28.7% weight loss at 68 weeks — the highest average figure ever reported in an obesity medication trial.
Retatrutide is not FDA-approved. As of August 2026, it remains investigational and available only through enrolled clinical trial participation. No telehealth provider can prescribe or dispense it. If Phase 3 results continue to be positive, an FDA submission could follow in late 2026 or 2027. Until then, it is not an option through Telezen MD or any other provider.
What the Clinical Trials Show
No three-way head-to-head trial exists as of August 2026. The results below come from three separate studies with different participant populations, durations, and designs. The closest direct comparison between any two of the three is SURMOUNT-5, which compared tirzepatide and semaglutide.
- Semaglutide (STEP 1, N Engl J Med 2021): 14.9% mean body weight loss at 68 weeks on 2.4mg weekly. The SELECT trial (2023) added a cardiovascular outcomes indication showing a 20% reduction in major cardiovascular events.
- Tirzepatide (SURMOUNT-1, N Engl J Med 2022): 20.9% mean body weight loss at 72 weeks on 15mg weekly. SURMOUNT-5 (2025) confirmed the advantage over semaglutide in a direct comparison.
- Retatrutide (Phase 2, N Engl J Med 2023; Phase 3 TRIUMPH-4, December 2025): 24.2% at 48 weeks in Phase 2; 28.7% at 68 weeks in the first Phase 3 result. Additional Phase 3 data is still accumulating.
Semaglutide vs Tirzepatide vs Retatrutide: Side-by-Side
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1 (1 receptor) | GLP-1 + GIP (2 receptors) | GLP-1 + GIP + Glucagon (3 receptors) |
| FDA Status | Approved | Approved | Investigational (Phase 3 — not approved) |
| Brand Names | Wegovy, Ozempic | Zepbound, Mounjaro | None (not yet approved) |
| Peak Trial Weight Loss | 14.9% (STEP 1, 68 wks, 2.4mg) | 20.9% (SURMOUNT-1, 72 wks, 15mg) | 28.7% Phase 3 / 24.2% Phase 2 (48 wks) |
| Dosing | Once weekly injection | Once weekly injection | Once weekly (trials only) |
| Cardiovascular Data | SELECT trial: 20% CVD risk reduction (approved indication) | SURPASS-CVOT ongoing; positive biomarker signals | No outcomes data yet |
| GI Side Effects | Nausea, constipation, diarrhea — well-characterized | Nausea 12-18% at high doses; dose-dependent | 50-60% GI adverse events at high Phase 2 dose |
| Available at Telezen MD | Yes — 503A FDA-regulated pharmacy | Yes — 503A FDA-regulated pharmacy | No — clinical trials only |
Side Effects: What to Expect From Each
All three share a gastrointestinal-dominant side-effect profile. Nausea is the most commonly reported symptom and tends to peak in the first four to eight weeks before improving as the body adjusts to each new dose level. Constipation, diarrhea, and occasional vomiting are also reported across all three.
Semaglutide has the most established long-term safety record of the three. Its side-effect profile is well-characterized across the STEP trial series and years of real-world use. GI effects are dose-dependent.
Tirzepatide showed nausea in roughly 12 to 18 percent of participants at the highest doses in Phase 3 trials. Gradual dose escalation over several months reduces the severity of early effects considerably.
Retatrutide showed gastrointestinal adverse events in 50 to 60 percent of participants at the highest Phase 2 dose — significantly higher than the two approved options. A 2025 network meta-analysis (Salhab et al., Journal of the Endocrine Society) found adverse events with retatrutide occurred at a relative risk of 4.10 versus tirzepatide. The glucagon component can also raise resting heart rate by approximately 5 to 10 beats per minute in some participants.
All three carry black-box warnings for thyroid C-cell tumor risk in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. None should be used during pregnancy.
FDA Approval and Availability in 2026
Semaglutide: Fully FDA-approved. Wegovy carries indications for chronic weight management and cardiovascular risk reduction. Available by prescription.
Tirzepatide: Fully FDA-approved. Zepbound carries indications for weight management and obstructive sleep apnea. Available by prescription.
Retatrutide: Not FDA-approved. Eli Lilly’s TRIUMPH Phase 3 program is underway. Until an FDA New Drug Application is reviewed and approved, retatrutide cannot be legally prescribed, dispensed, or offered by any telehealth provider.
Products sold online as “retatrutide” outside of clinical trials are not the pharmaceutical-grade investigational compound. They are unregulated and unverified. Telezen MD does not offer or recommend them.
What Telezen MD Offers Right Now
Starting semaglutide or tirzepatide is a meaningful step. What happens alongside it — nutrition adjustments, behavioral change, and ongoing clinical support — shapes how lasting that progress becomes.
Telezen MD patients have access to two programs most GLP-1 providers do not offer:
The GLP-1 Nutrition Protocolâ„¢ is a seven-module, 26-lesson course built specifically for GLP-1 users. It covers how to eat in a way that supports the medication’s mechanism, preserves muscle, and builds long-term metabolic health. Free for all Telezen patients.
Lose It for Lifeâ„¢ is a 10-module behavior change program developed by Lina Viner using The Rewire Methodâ„¢. It addresses the psychological patterns behind overeating and builds lasting lifestyle change from within.
“Medical science takes the weight off. Mind science keeps it off.”
Also free for Telezen patients. Telezen MD also provides concierge-level support — your medical team is accessible throughout treatment, not just at the point of prescription.
How Getting Started Works
The process is designed to fit your life:
- Complete a brief intake form with your medical history.
- Choose the plan that fits your goals.
- Submit your intake for review.
- A licensed healthcare provider reviews your information and, if appropriate, issues a prescription — typically within 24 hours.
- Your medication ships from a 503A FDA-regulated pharmacy directly to your door.
No clinic visit. No bloodwork required. Your provider stays with you throughout.
Ready to get started? Visit telezenmd.com/semaglutide or telezenmd.com/tirzepatide-prescription-online to take the next step.
Frequently Asked Questions
What is the difference between semaglutide, tirzepatide, and retatrutide?
Semaglutide is a GLP-1 receptor agonist targeting one hormone pathway. Tirzepatide adds a second — GIP — making it a dual agonist. Retatrutide adds a third — glucagon — making it a triple agonist. Each added target has tracked with greater average weight loss in separate trials, though no three-way head-to-head study exists yet.
Is retatrutide available to patients in 2026?
No. As of August 2026, retatrutide remains an investigational drug available only through enrolled clinical trial participation. No telehealth provider, including Telezen MD, can legally prescribe or dispense it. The earliest a potential FDA submission could occur is late 2026 or 2027, depending on Phase 3 outcomes.
Which medication produces the most weight loss?
In clinical trials, retatrutide has shown the highest figures — 24.2% in Phase 2 and 28.7% in the first Phase 3 result. Among the two currently approved options, tirzepatide produced greater average weight loss than semaglutide in the head-to-head SURMOUNT-5 trial (20.2% vs 13.7% at 72 weeks). Individual responses vary and these figures come from different trial designs.
Can I switch from semaglutide to tirzepatide?
Yes. Some patients switch after plateauing on semaglutide. There is no mandatory washout period, but the transition should be managed by a licensed provider to handle dose conversion and monitor for any changes in side effects. Telezen MD’s clinical team can support this process.
What side effects should I expect on these medications?
Nausea is the most common side effect across all three. Constipation, diarrhea, and occasional vomiting are also reported. Effects are dose-dependent and most pronounced in the first several weeks as the body adjusts. Retatrutide showed a higher GI adverse event rate in Phase 2 than either approved option. Gradual dose escalation reduces these effects with all three medications.
Does tirzepatide work better than semaglutide for weight loss?
In SURMOUNT-5 — the only direct head-to-head trial — tirzepatide at 15mg produced 20.2% weight loss versus 13.7% for semaglutide at 2.4mg over 72 weeks. That is a meaningful clinical difference. However, semaglutide has more established cardiovascular outcomes data, which may be the deciding factor for certain patients. The best choice depends on your health history and goals.
The Bottom Line
Semaglutide is the most extensively studied option and the only weight-loss medication with a cardiovascular outcomes indication. Tirzepatide produced greater average weight loss in trials and in the only direct comparison between the two. Retatrutide has shown the highest weight-loss figures ever recorded in an obesity drug trial — but it is not approved, not available outside clinical trials, and carries a meaningfully higher adverse event burden than either approved option.
For patients ready to act now, semaglutide and tirzepatide are both accessible through Telezen MD, compounded through 503A FDA-regulated pharmacies and supported by programs that address both the biological and behavioral dimensions of sustained weight loss.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36. doi:10.1056/NEJMoa2416394
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563
- Salhab A et al. Comparative Efficacy and Safety of Tirzepatide vs Retatrutide: A Network Meta-Analysis. J Endocr Soc. 2025;9(Suppl 1):bvaf149.169. doi:10.1210/jendso/bvaf149.169
- Eli Lilly and Company. Lilly’s Triple Agonist Retatrutide Delivered Weight Loss of up to an Average of 71.2 lbs in First Successful Phase 3 Trial. Press Release. December 2025.
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. GLP-1 medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.
